GO:0007224 smoothened signaling pathway: Hedgehog Signal Transduction, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007224 (smoothened signaling pathway) describes the intracellular signal transduction cascade triggered by the Hedgehog ligand and transduced by the GPCR-like protein Smoothened (SMO).
• The pathway is a central regulator of embryonic development, stem cell maintenance, and tissue homeostasis, and its aberrant activation drives cancers such as basal cell carcinoma and medulloblastoma.
• SMO activation requires cholesterol modification and ciliary trafficking, linking the pathway to the primary cilium and to proteostasis networks.
• Pharmacological SMO inhibitors (e.g., vismodegib, sonidegib) are clinically approved but resistance frequently emerges through SMO mutations or downstream transcriptional rewiring.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting SMO-dependent signaling and for validating resistance mechanisms.
• The pathway is best studied with a combination of ciliary imaging, transcriptional reporter assays, and genome-wide CRISPR screens.
Description
GO:0007224, the smoothened signaling pathway, is the biological process through which the Hedgehog (HH) signal is relayed from the cell surface to the nucleus via the seven-transmembrane protein Smoothened (SMO). In the absence of HH ligand, the receptor Patched1 (PTCH1) suppresses SMO; upon ligand binding, PTCH1 is internalized and SMO becomes active, accumulating in the primary cilium and initiating a cascade that controls GLI transcription factors. This pathway is one of the most intensely studied developmental signaling systems because of its roles in embryogenesis, tissue patterning, and adult stem cell biology. For researchers, GO:0007224 is a paradigm for understanding how a GPCR-like protein can be regulated by a sterol-sensing receptor and by cholesterol modification. The pathway also serves as a clinically actionable target: aberrant SMO signaling is a hallmark of basal cell carcinoma and a subset of medulloblastoma, and SMO inhibitors are approved therapeutics. However, resistance to these inhibitors is common, driving interest in combination therapies and in the transcriptional dependencies that sustain pathway output. This article synthesizes the authoritative GO annotation for GO:0007224 with verified PubMed literature to provide a research-grade overview of the pathway's mechanism, key genes, disease links, and the CRISPR-based methods used to study it.
smoothened signaling pathway At A Glance
| GO ID | GO:0007224 |
|---|---|
| GO term | smoothened signaling pathway |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Transduces Hedgehog signals from the cell surface to GLI transcription factors, controlling cell fate, proliferation, and differentiation |
| Key upstream regulator | Patched1 (PTCH1) inhibits SMO in the absence of Hedgehog ligand |
| Key downstream effectors | GLI1, GLI2, GLI3 transcription factors |
| Subcellular site | Primary cilium and cytoplasm |
| Clinical relevance | Aberrant activation in basal cell carcinoma and medulloblastoma; target of SMO inhibitors |
What Is GO:0007224?
The smoothened signaling pathway (GO:0007224) is the series of molecular events in which the Hedgehog ligand relieves Patched-mediated inhibition of Smoothened, allowing Smoothened to activate downstream GLI transcription factors and thereby regulate target gene expression. This process encompasses ligand reception, Smoothened activation and ciliary accumulation, and the subsequent modulation of GLI proteins.
Why Is smoothened signaling pathway Important in Cell Biology?
GO:0007224 is critically important because it governs fundamental developmental decisions and is one of the most frequently dysregulated pathways in human cancer. Understanding its mechanism has led to approved drugs for basal cell carcinoma and medulloblastoma, yet resistance remains a major clinical challenge, making continued research into SMO regulation and downstream dependencies essential.
• Controls embryonic patterning and organogenesis, including neural tube and limb development.
• Maintains adult stem cell populations and tissue homeostasis.
• Constitutively activated in basal cell carcinoma, often through PTCH1 or SMO mutations.
• Drives a subset of medulloblastoma, particularly the SHH subgroup.
• SMO is the target of approved inhibitors vismodegib and sonidegib.
• Resistance to SMO inhibitors occurs via SMO mutations or downstream transcriptional changes.
• Cholesterol modification of SMO is required for pathway activity, linking lipid metabolism to signaling.
• Proteostasis networks regulate SMO stability and ciliary trafficking.
• The primary cilium is a specialized platform for SMO signaling, connecting ciliopathies to Hedgehog dysregulation.
• CRISPR screens have identified super-enhancer-driven transcriptional dependencies that sustain aberrant Hedgehog activation.
What Happens During smoothened signaling pathway?
Ligand reception and relief of Patched-mediated inhibition
In simple terms: When the Hedgehog signal arrives, it stops a brake called Patched from holding back Smoothened.
In the absence of Hedgehog (HH) ligand, the twelve-transmembrane protein Patched1 (PTCH1) localizes to the primary cilium and prevents Smoothened (SMO) from entering the cilium, thereby keeping the pathway off. Binding of HH ligand to PTCH1 triggers PTCH1 internalization and degradation, relieving the inhibition of SMO. This step is the first committed event in GO:0007224 and is regulated by the availability of HH ligand and by ciliary trafficking machinery.
Smoothened activation and ciliary accumulation
In simple terms: Once freed, Smoothened moves into the primary cilium and becomes active.
Upon relief of PTCH1 inhibition, SMO undergoes conformational changes and accumulates in the primary cilium, a process that requires cholesterol modification of SMO. Cholesterol modification of SMO is essential for Hedgehog signaling, as it promotes SMO ciliary localization and activation. Proteostasis factors, including chaperones and ubiquitin ligases, regulate SMO stability and its transit to the cilium. This step represents the core activation event of GO:0007224.
GLI transcription factor processing and activation
In simple terms: Active Smoothened sends a message that turns GLI proteins into gene activators.
Active SMO promotes the dissociation of GLI transcription factors (GLI1, GLI2, GLI3) from Suppressor of Fused (SUFU), allowing full-length GLI proteins to enter the nucleus and activate target genes. In the off state, GLI proteins are phosphorylated by PKA, CK1, and GSK3, leading to partial proteolytic processing into repressors. The balance between GLI activator and repressor forms determines the transcriptional output of GO:0007224.
Transcriptional feedback and pathway output
In simple terms: The pathway turns on genes that can also feed back to tune its own strength.
GLI activation induces target genes including GLI1, PTCH1, and CCND1, which drive proliferation and cell fate changes. PTCH1 and GLI1 themselves are canonical transcriptional targets, creating negative and positive feedback loops that shape pathway dynamics. Super-enhancer-driven transcriptional dependencies can sustain aberrant Hedgehog pathway activation and contribute to resistance to SMO inhibitors. This step defines the downstream biological consequences of GO:0007224.
Key Genes Involved in GO:0007224 smoothened signaling pathway
The smoothened signaling pathway involves a core set of ligand, receptor, and effector genes whose functions are well documented in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SHH | Secreted Hedgehog ligand that initiates pathway activation | Key upstream signal; knockout models show developmental defects |
| PTCH1 | Patched receptor that inhibits SMO in the absence of ligand | Tumor suppressor; frequently mutated in basal cell carcinoma |
| SMO | Smoothened, GPCR-like transducer of the Hedgehog signal | Drug target; mutations cause resistance to inhibitors |
| GLI1 | Transcriptional activator and target gene of the pathway | Readout of pathway activity; amplified in cancers |
| GLI2 | Primary transcriptional activator of Hedgehog target genes | Essential for pathway output; knockout is embryonic lethal |
| GLI3 | Bifunctional transcription factor, mainly repressor form | Regulates limb and neural patterning |
| SUFU | Suppressor of Fused, negative regulator of GLI proteins | Tumor suppressor; mutations in medulloblastoma |
| KIF7 | Kinesin motor that regulates GLI processing at the cilium | Ciliopathy-related; modulates pathway strength |
| IFT88 | Intraflagellar transport protein required for ciliogenesis | Loss disrupts SMO ciliary localization |
| PKA (PRKACA) | Phosphorylates GLI proteins to promote repressor formation | Negative regulator; modulates pathway threshold |
| CK1 (CSNK1A1) | Phosphorylates GLI proteins in the absence of signal | Part of the GLI destruction complex |
| GSK3B | Phosphorylates GLI proteins to promote processing | Negative regulator of GLI activators |
| BTRC (β-TrCP) | E3 ubiquitin ligase that targets GLI proteins for processing | Regulates GLI repressor generation |
| STK36 (FU) | Serine/threonine kinase that modulates GLI activity | Positive regulator of pathway output |
| CCND1 | Cyclin D1, a GLI target gene driving proliferation | Links pathway to cell cycle progression |
| MYCN | Oncogene amplified in medulloblastoma, interacts with SHH signaling | Biomarker in SHH medulloblastoma |
| BRD4 | Super-enhancer reader that sustains Hedgehog transcriptional output | Target for overcoming SMO inhibitor resistance |
How Is smoothened signaling pathway Regulated?
The smoothened signaling pathway is regulated at multiple levels. Cholesterol modification of SMO is required for its ciliary accumulation and activity. Proteostasis networks, including chaperones and the ubiquitin-proteasome system, control SMO stability and trafficking. The primary cilium serves as a specialized signaling platform where SMO, GLI proteins, and SUFU dynamically interact. Transcriptional feedback loops involving GLI1 and PTCH1 tune pathway intensity. In cancer, super-enhancer-driven transcriptional dependencies can sustain pathway activation and mediate resistance to SMO inhibitors.
smoothened signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTCH1 | Basal cell carcinoma, medulloblastoma | PTCH1 knockout or point-mutation cell lines |
| SMO | Basal cell carcinoma, resistance to SMO inhibitors | SMO point-mutation knock-in (e.g., D473H) |
| SUFU | Medulloblastoma (SHH subgroup) | SUFU knockout medulloblastoma models |
| GLI1 | Amplified in various cancers, pathway readout | GLI1 overexpression or reporter knock-in |
| KIF7 | Ciliopathies with Hedgehog dysregulation | KIF7 knockout cells for ciliary assays |
Basal cell carcinoma
Aberrant activation of the smoothened signaling pathway is the principal driver of basal cell carcinoma (BCC), most commonly through loss-of-function mutations in PTCH1 or activating mutations in SMO. SMO inhibitors such as vismodegib and sonidegib are approved for advanced BCC, but resistance frequently emerges through secondary SMO mutations or downstream pathway reactivation. Molecular tumor profiling is increasingly used to identify resistance mechanisms and guide therapy.
Medulloblastoma
The SHH subgroup of medulloblastoma is driven by constitutive Hedgehog pathway activation, often involving PTCH1 or SUFU mutations. These tumors typically occur in infants and adults and require multimodal therapy. Targeting SMO has shown efficacy but resistance and toxicity limit long-term benefit, prompting research into downstream dependencies.
Developmental disorders and ciliopathies
Because GO:0007224 is essential for embryonic patterning, disruptions in pathway components cause developmental defects. Mutations affecting primary cilium function, such as in KIF7 or IFT88, can dysregulate Hedgehog signaling and contribute to ciliopathies with skeletal and neural abnormalities.
From smoothened signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SMO abolish Hedgehog signaling? | SMO knockout cell line |
| Does a specific SMO mutation confer inhibitor resistance? | SMO point-mutation knock-in (e.g., D473H) |
| How does cholesterol modification affect SMO function? | SMO knock-in with cholesterol-site mutation |
| What is the transcriptional output of pathway activation? | GLI-luciferase reporter knock-in or overexpression |
| Which genes are required for SMO ciliary localization? | Genome-wide CRISPR knockout library screen |
| How does SUFU loss affect medulloblastoma growth? | SUFU knockout mouse or cell line |
How to Study the smoothened signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GLI-luciferase reporter | Transcriptional activity of GLI factors | Pathway activation in response to ligand or inhibitors |
| Immunofluorescence | Ciliary localization of SMO and GLI proteins | Assessment of pathway activation state |
| CRISPR knockout screen | Genes required for pathway activity or resistance | Discovery of novel regulators and resistance mechanisms |
| Co-immunoprecipitation | Protein-protein interactions (e.g., SMO-SUFU) | Mechanistic studies of pathway components |
| Western blot | GLI processing and SMO stability | Evaluation of pathway modulation |
| qRT-PCR | Expression of GLI1, PTCH1 target genes | Pathway activity readout |
| Cholesterol modification assay | SMO lipidation status | Study of SMO activation requirements |
| Molecular tumor profiling | Mutations in SMO, PTCH1, SUFU | Clinical identification of resistance mechanisms |
Transcriptional reporter assays
GLI-dependent luciferase reporters are widely used to measure smoothened signaling pathway activity in cells. These assays can be combined with CRISPR knockout of candidate genes to determine their requirement for pathway activation.
Ciliary imaging and immunofluorescence
Because SMO accumulates in the primary cilium upon activation, immunofluorescence microscopy of ciliary markers (e.g., acetylated tubulin) and SMO is a standard method to assess pathway activation. This approach is particularly useful for studying cholesterol modification and trafficking mutants.
Genome-wide CRISPR screens
CRISPR knockout library screens have been used to identify genes that regulate Hedgehog signaling and to uncover super-enhancer-driven transcriptional dependencies that mediate resistance to SMO inhibitors. These screens provide unbiased insights into pathway regulation.
Proteomic and biochemical assays
Co-immunoprecipitation, ubiquitination assays, and proteomic profiling are used to study SMO stability, GLI processing, and interactions with proteostasis machinery. These methods help define the molecular mechanisms of GO:0007224.
How CRISPR Can Be Used to Study GO:0007224 smoothened signaling pathway
Knockout
CRISPR knockout of SMO, PTCH1, or GLI genes is used to establish their requirement for smoothened signaling pathway activity. For example, SMO knockout abolishes Hedgehog-induced GLI reporter activity, while PTCH1 knockout leads to constitutive pathway activation. Genome-wide knockout screens have identified additional genes that modulate pathway output.
Point Mutation
Point-mutation knock-in models, such as SMO D473H, are valuable for studying resistance to SMO inhibitors like vismodegib. These models allow researchers to test whether specific mutations confer drug resistance and to evaluate second-line therapies.
Knock-in
Knock-in of reporter genes (e.g., luciferase or fluorescent proteins) into GLI target loci enables real-time monitoring of pathway activity. Knock-in of cholesterol-modification site mutations in SMO helps dissect the role of lipidation in pathway activation.
Overexpression
Overexpression of GLI1 or GLI2 can drive constitutive pathway activation and is used to model downstream activation independent of SMO. Overexpression of SMO mutants can also mimic tumor-associated activation.
How EDITGENE Supports smoothened signaling pathway Research
Researchers studying smoothened signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, drug resistance, or tumor growth. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for smoothened signaling pathway research.
Frequently Asked Questions About smoothened signaling pathway
What is the smoothened signaling pathway?
The smoothened signaling pathway (GO:0007224) is the intracellular cascade that relays Hedgehog signals from the cell surface to GLI transcription factors via the Smoothened protein.
What genes are involved in smoothened signaling pathway?
Key genes include SHH, PTCH1, SMO, GLI1, GLI2, GLI3, SUFU, KIF7, and IFT88, among others.
What is the role of SMO in Hedgehog signaling?
SMO is the central transducer; upon relief of PTCH1 inhibition, it accumulates in the primary cilium and activates GLI proteins.
How is smoothened signaling pathway regulated?
It is regulated by cholesterol modification of SMO, proteostasis networks, ciliary trafficking, and transcriptional feedback loops.
What diseases are associated with smoothened signaling pathway?
Aberrant activation causes basal cell carcinoma and medulloblastoma; loss of function contributes to developmental disorders.
Why is cholesterol important for smoothened signaling?
Cholesterol modification of SMO is required for its ciliary localization and activation, making it essential for pathway activity.
How do SMO inhibitors work?
SMO inhibitors such as vismodegib bind SMO and block its activity, but resistance can arise through SMO mutations or downstream changes.
What is the primary cilium's role in smoothened signaling?
The primary cilium serves as a signaling hub where SMO, GLI proteins, and SUFU interact; disruption of cilia impairs pathway activation.
How can CRISPR be used to study smoothened signaling pathway?
CRISPR knockout, point-mutation knock-in, and overexpression models allow researchers to test gene function and drug resistance in pathway components.
What are the current challenges in targeting smoothened signaling pathway?
Resistance to SMO inhibitors and toxicity remain major challenges, driving research into downstream dependencies and combination therapies.
Conclusion
GO:0007224, the smoothened signaling pathway, is a fundamental developmental cascade with profound implications for cancer and tissue homeostasis. Its core mechanism, from PTCH1-mediated inhibition of SMO to GLI-driven transcription, is well defined and clinically actionable. However, resistance to SMO inhibitors highlights the need for deeper understanding of pathway regulation and downstream dependencies. CRISPR-based models will continue to be indispensable for dissecting these mechanisms and for developing next-generation therapies.
References
- 1. Skoda AM et al.. 2018. The role of the Hedgehog signaling pathway in cancer: A comprehensive review.. Bosn J Basic Med Sci 18(1):8-20 PMID: 29274272
- 2. Xiao X et al.. 2017. Cholesterol Modification of Smoothened Is Required for Hedgehog Signaling.. Mol Cell 66(1):154-162.e10 PMID: 28344083
- 3. Juraschka K et al.. 2019. Medulloblastoma in the age of molecular subgroups: a review.. J Neurosurg Pediatr 24(4):353-363 PMID: 31574483
- 4. Liu A. 2019. Proteostasis in the Hedgehog signaling pathway.. Semin Cell Dev Biol 93:153-163 PMID: 31429406
- 5. Gigante ED et al.. 2020. Signaling in the primary cilium through the lens of the Hedgehog pathway.. Wiley Interdiscip Rev Dev Biol 9(6):e377 PMID: 32084300
- 6. Sui Y et al.. 2024. Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance.. Cancer Res 84(16):2690-2706 PMID: 38775809
- 7. Basset-Seguin N. 2018. Traitement médical des carcinomes basocellulaires avancés: Medical treatment of advanced basal cell carcinoma.. Ann Dermatol Venereol 145 Suppl 5:VS36-VS41 PMID: 30477683
- 8. Papaccio F et al.. 2025. Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.. Int J Mol Sci 27(1) PMID: 41515948
